Tigecycline's Action Against MRSA
Tigecycline, a glycylcycline antibiotic, inhibits MRSA growth by binding to the 30S ribosomal subunit in bacteria, blocking protein synthesis at the initiation stage.[1] This prevents the attachment of aminoacyl-tRNA to the ribosomal A site, halting translation and starving the bacteria of essential proteins for replication and survival.
How It Differs from Older Tetracyclines
Unlike tetracyclines, which MRSA often resists via efflux pumps or ribosomal protection, tigecycline has structural tweaks—a fused glycylamido group and a carbamoyl side chain—that enable tighter binding to the ribosome and evasion of common resistance mechanisms.[1][2] It remains effective against many tetracycline-resistant MRSA strains.
Does It Kill MRSA or Just Stop Growth?
Tigecycline is bacteriostatic against MRSA, meaning it inhibits growth without directly killing the bacteria—clearance depends on the host immune response.[1] Clinical breakpoints for susceptible MRSA are MIC ≤0.5 μg/mL (CLSI standards).[3]
MRSA Resistance Mechanisms to Tigecycline
Resistance is rare but emerging via ribosomal mutations (e.g., rpsJ gene) or efflux overexpression. Most MRSA retains susceptibility, with MIC90 around 0.5-1 μg/mL in surveillance data.[2][4]
Clinical Use for MRSA Infections
Tigecycline treats complicated skin/skin-structure infections and intra-abdominal infections caused by MRSA, dosed IV at 100 mg load then 50 mg q12h. It's reserved for multidrug-resistant cases due to FDA warnings on mortality risk in certain infections.[5]
[1]: Tigecycline mechanism - FDA Label
[2]: Glycylcyclines review - Clinical Microbiology Reviews
[3]: CLSI M100 breakpoints
[4]: SENTRY Antimicrobial Surveillance
[5]: Tygacil prescribing info